A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CNTX-6016 in Healthy Subjects and a Single Cohort of Subjects With Painful Diabetic Neuropathy
Latest Information Update: 06 Nov 2023
Price :
$35 *
At a glance
- Drugs CNTX 6016 (Primary)
- Indications Diabetic neuropathies
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Centrexion Therapeutics
- 30 Oct 2023 The protocol has been amended to change in phase from phase I/II to Phase I.
- 30 Oct 2023 Status changed from recruiting to completed.
- 22 Apr 2021 Status changed from planning to recruiting.